Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × lanreotide × Endocrine × Clear all

Phase

Phase 3 7 Phase 2 7 Phase 4 4 Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

gallium Ga 68 dotatate 6 90Y-octreotide, DOTA-Tyr(3)- 3 Magnetic Resonance Spectroscopy 2 3-Iodobenzylguanidine 2 trametinib 1 sacubitril and valsartan sodium hydrate drug combination 1 lutetium Lu 177 dotatate 1 lanreotide 1 corticorelin ovine 1 Tomography, X-Ray Computed 1 Tomography, Emission-Computed, Single-Photon 1 Sitagliptin Phosphate 1 Single Photon Emission Computed Tomography Computed Tomography 1 Positron-Emission Tomography 1 Positron Emission Tomography Computed Tomography 1 Paclitaxel 1 Microscopy, Electron 1 Metformin 1 Liraglutide 1 Iodine-123 1 Ga(III)-DOTATOC 1 CYT-6091 1 68Ga-pentixafor 1 68Ga-FAPI 1 64Cu-SARTATE 1 6-fluorodopamine 1 3-fluorobenzylguanidine 1 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02823691 2021-06-07

MetNET-2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase EARLY_PHASE1 Unknown

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡